Concord Biotech Base Case Target Achieved
Authored By Prime Research | Published at: Aug 18, 2026 11:36 AM IST
Stocks in News
Open Free Demat Account
In our quarterly result update report dated Aug 08, 2026 we had recommended to buy Concord Biotech in the band of Rs 1360-1382 band and add on dips in Rs 1239-1252 band for a base case fair value of Rs 1539 and a bull case fair value of Rs 1658 over the next 4 quarters.
Today, the stock hit a high of Rs 1576, thereby achieving our base case target and yielding a return of 11.4% in just seven trading sessions.
Disclaimer
At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please Note: The information shared is intended solely for informational purposes and does not make any investment recommendations
If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.
Please Note: The information shared is intended solely for informational purposes and does not make any investment recommendations
Join Us
Add as preferred source on Google
